Fig. 4.
Fig. 4. Grafts from tumor-bearing donors can mediate a graft-versus-tumor effect. / (A) Tumor-bearing BALB/c donor mice were challenged 14 days prior to graft harvest, and all recipients were challenged 10 days prior to transplant with 1 × 106 A20 wild-type tumor cells given intravenously. BM and spleens were harvested from the donors, and tumor was depleted as described in “Materials and methods.” Recipient mice were irradiated, reconstituted with the purged grafts, and followed twice weekly for the progression of tumor. (B) Donor BALB/c mice received 2.5 × 106anti-HA–specific T cells with or without a tumor challenge (1 × 106 A20HA cells intravenously) 25 days before graft harvest. BM and spleens from both groups were harvested and tumor depleted as described. Recipient mice were challenged with 1 × 106 A20HA cells 10 days before being irradiated, transplanted with the purged grafts from non–tumor-bearing or non–tumor-bearing donors, and followed for tumor progression.

Grafts from tumor-bearing donors can mediate a graft-versus-tumor effect.

(A) Tumor-bearing BALB/c donor mice were challenged 14 days prior to graft harvest, and all recipients were challenged 10 days prior to transplant with 1 × 106 A20 wild-type tumor cells given intravenously. BM and spleens were harvested from the donors, and tumor was depleted as described in “Materials and methods.” Recipient mice were irradiated, reconstituted with the purged grafts, and followed twice weekly for the progression of tumor. (B) Donor BALB/c mice received 2.5 × 106anti-HA–specific T cells with or without a tumor challenge (1 × 106 A20HA cells intravenously) 25 days before graft harvest. BM and spleens from both groups were harvested and tumor depleted as described. Recipient mice were challenged with 1 × 106 A20HA cells 10 days before being irradiated, transplanted with the purged grafts from non–tumor-bearing or non–tumor-bearing donors, and followed for tumor progression.

Close Modal

or Create an Account

Close Modal
Close Modal